While its normal to lose some muscle during weight loss, the study found that this can be reduced when treatment is guided by an obesity specialist
As these medications become among the most widely prescribed in the world, the ability to tailor treatment based on genetic profile or to target specific clinical outcomes such as cardiovascular risk reduction could transform prescribing practices well beyond their current primary use in obesity and diabetes management Sources New 23andMe Research Institute Study Identifies Genetic Predictors for GLP-1 Weight Loss Efficacy and Side Effects 23andME April 8, 2026 Genetic variations linked to weight loss, side effects from GLP-1 drugs Reuters April 10, 2026
Seeley said, referring to carefully testing every potential indication before it is enthusiastically taken up
Ideal para quienes quieren empezar un cambio o potenciar lo que ya vienen haciendo
For example, tirzepatide may reduce the effectiveness of oral contraceptives, and patients taking warfarin with any GLP-1 receptor agonist should consider more frequent INR monitoring when starting or stopping therapy
Frustrated with having a label